Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trametinib and Pazopanib in Advanced GIST
NCT02342600Phase 2Withdrawn
- Sponsor
- Sarcoma Alliance for Research through Collaboration
- Start
- Jan 2017
- Primary completion
- Jan 2020
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of trametinib and pazopanib in gastrointestinal stromal tumor (GIST), sponsored by Sarcoma Alliance for Research through Collaboration. Primary endpoint: Disease Control Rate at 16 weeks. Planned start Jan 2017; status: withdrawn.
02
Drugs
trametinibpazopanib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT02342600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02342600.